A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients
Status:
Recruiting
Trial end date:
2024-12-06
Target enrollment:
Participant gender:
Summary
Primary objective:
● To evaluate the efficacy of pemigatinib in advanced non-small cell lung cancer patients
with fibroblast growth factor receptor 1-3 (FGFR 1-3) alterations (including but not limited
to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard
therapy.
Secondary objective:
● To evaluate the safety and tolerability of pemigatinib in advanced non-small cell lung
cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR
amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy,
including the incidence of adverse events (AEs) and serious adverse events (SAEs), as well as
the incidence of AEs/SAEs resulting in treatment discontinuation.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University